[Federal Register: July 10, 2002 (Volume 67, Number 132)]
[Notices]
[Page 45742-45743]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10jy02-96]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 02N-0209]
Request for Comment on First Amendment Issues
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; extension of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is extending to
September 13, 2002, the comment period for original comments and is
extending to October 28, 2002, the comment period for responses to
those comments relating to FDA's Request for Comment on First Amendment
Issues published in the Federal Register of May 16, 2002 (67 FR 34942).
The agency is taking this action in response to requests for an
extension.
DATES: Submit written or electronic comments on the Request for Comment
on First Amendment Issues by September 13, 2002, and submit written or
electronic responses to those comments by October 28, 2002.
ADDRESSES: Submit written comments to the Dockets Management Branch
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm.
[[Page 45743]]
1061, Rockville, MD 20852. Submit electronic comments to http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Catherine Lorraine, Office of Policy,
Planning, and Legislation (HF-11), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-3360.
SUPPLEMENTARY INFORMATION: In the Federal Register of May 16, 2002 (67
FR 34942), FDA published a document entitled ``Request for Comment on
First Amendment Issues.'' In this document FDA asked the public to
comment on a number of questions to help ensure that the agency's
regulations, guidances, policies, and practices continue to comply with
the governing First Amendment case law. Recent case law has emphasized
the need for not imposing unnecessary restrictions on speech. The
document also stated the agency's wish to learn what empirical evidence
exists concerning, among other things, the effect of commercial speech
on the public health.
The agency received three letters requesting that the agency extend
the comment period for 60 days until September 30, 2002, for the
submission of comments and until November 13, 2002, for the submission
of responses to the comments. The three requests cited the need for
additional time because of the complexity and importance of the subject
matter to be commented on. The requests also stated an extension was
needed to enable consultation with a variety of individuals, including
social science and other experts, as well as business partners. One
request pointed out that summer vacation schedules would make this
consultation even more difficult. FDA has determined that it is
appropriate to grant these requests. However, FDA believes that an
additional 45 days will be sufficient time to allow for the
consultations discussed and the preparation of comments.
Interested persons may submit to the Dockets Management Branch (see
ADDRESSES) written or electronic comments on the document requesting
comment on First Amendment issues by September 13, 2002, and responses
to comments by October 28, 2002. Three copies of any comments are to be
submitted, except that individuals may submit one copy. Comments are to
be identified with the docket number found in brackets in the heading
of this document. Comments and responses to comments may be seen in the
Dockets Management Branch between 9 a.m. and 4 p.m., Monday through
Friday.
Dated: July 3, 2002.
William K. Hubbard,
Senior Associate Commissioner for Policy, Planning, and Legislation.
[FR Doc. 02-17275 Filed 7-9-02; 8:45 am]
BILLING CODE 4160-01-S